Technology | Heart Valve Technology | November 09, 2017

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

Device employs a unique supra-annular, atrial-only fixation approach

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

November 9, 2017 — 4C Medical Technologies Inc. announced that its medical device for mitral regurgitation (MR) was presented at the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, held Oct. 29-Nov. 2, 2017 in Denver. The device was one of the eight innovations selected among nearly fifty submissions.

4C Medical is developing the first MR treatment that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates issues associated with current transcatheter mitral valve replacement (TMVR) technologies – which rely on placement and fixation in the native mitral annulus and left ventricle – such as obstruction of the left ventricular outflow tract, impaired function of the left ventricle and device embolization.

Philippe Généreux, M.D., presented "A Novel Transcatheter Mitral Valve Replacement Technology (4C)," in which he explained how the design and supra-annular placement of the 4C valve may extend TMVR therapy to patients who would be ineligible for alternative TMVR procedures based on the irregular anatomy of their mitral annulus or left ventricle or presence of severe calcification. Généreux is co-director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, N.J.) and a practicing interventional cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

Watch the VIDEO “TAVR For Asymptomatic Severe Aortic Stenosis,” an interview with Généreux at TCT 2017.

"One aspect that excites me most about the 4C valve is that it is the only scalable technology that will provide treatment options for a broad MR patient population," said Généreux. "Because the device is placed and anchored entirely in the left atrium, it does not rely on or interact with the dynamic and irregular anatomy of the mitral annulus and left ventricle. Additionally, the 4C valve may be delivered transapically or transseptally, which gives options to operators. No other valve in development today can offer the same advantages. 4C Medical's technology will answer a real unmet clinical need."

Watch the VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch at TCT 2017  — with Juan Granada, M.D.

For more information: www.4cmed.com


Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now